Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
Seres Therapeutics has reported its Q4 and full-year 2024 financial results. The company received positive FDA feedback on its SER-155 study, supporting the primary efficacy endpoint. Seres plans to submit a draft study protocol to the FDA in Q2 2025.
March 13, 2025 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics received positive FDA feedback on its SER-155 study, supporting the primary efficacy endpoint. The company plans to submit a draft study protocol in Q2 2025.
The positive FDA feedback on the SER-155 study is a significant regulatory milestone for Seres Therapeutics, likely boosting investor confidence and potentially impacting the stock price positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90